Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Novartis
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
AstraZeneca
Ipsen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Emory University
OHSU Knight Cancer Institute
SWOG Cancer Research Network
Palleos Healthcare GmbH
Hoffmann-La Roche
Emory University
Massachusetts General Hospital
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Gilead Sciences
Corcept Therapeutics
Merck Sharp & Dohme LLC
Virginia Commonwealth University
Emory University
University of Iowa
City of Hope Medical Center
University of Colorado, Denver
University of Chicago
City of Hope Medical Center
NGM Biopharmaceuticals, Inc
Thomas Jefferson University
Precision Biologics, Inc
University of Chicago
Pancreatic Cancer Action Network
Thomas Jefferson University
Columbia University
Washington University School of Medicine
NYU Langone Health
University of Michigan Rogel Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Immodulon Therapeutics Ltd
Kyntra Bio
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
US Oncology Research
Merck Sharp & Dohme LLC